Tenaya Therapeutics Completes Launch Of Genetic Medicines Manufacturing Center
Tenaya Therapeutics Completes Launch Of Genetic Medicines Manufacturing Center
Tenaya Therapeutics, Inc. (NASDAQ:TNYA), a biotechnology company with a mission to discover, develop and deliver curative therapies that address the underlying causes of heart disease, today announced that it has completed the build-out and operational launch of its Genetic Medicines Manufacturing Center in Union City, California. Tenaya is advancing a pipeline of therapeutic candidates, including several adeno-associated virus (AAV) gene therapies, for the potential treatment of both rare and prevalent forms of heart disease.
Tenaya Therapeutics, Inc. (NASDAQ:TNYA), a biotechnology company with a mission to discover, develop and deliver curative therapies that address the underlying causes of heart disease, today announced that it has completed the build-out and operational launch of its Genetic Medicines Manufacturing Center in Union City, California. Tenaya is advancing a pipeline of therapeutic candidates, including several adeno-associated virus (AAV) gene therapies, for the potential treatment of both rare and prevalent forms of heart disease.
亞洲網加利福尼亞州米爾皮塔斯2月23日電以發現、開發和提供治療心臟病根本原因的根治療法為使命的生物技術公司田納亞治療公司(納斯達克代碼:TNYA)今天宣佈,它已經完成了位於加利福尼亞州聯合城的基因藥物製造中心的擴建和運營啟動。Tenaya正在推進一系列候選治療方法,包括幾種腺相關病毒(AAV)基因療法,用於治療罕見和流行形式的心臟病。
譯文內容由第三人軟體翻譯。
風險及免責聲明
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧